Publications by authors named "Jaszianne Tolbert"
Article Synopsis
- Cytokine release syndrome, often linked to T-cell therapies like talquetamab, causes an increase in interleukin-6 (IL-6), which might inhibit certain liver enzymes (cytochrome P450).
- The study aimed to assess how elevated IL-6 affects the metabolism of other drugs by looking at both standard and extreme IL-6 levels after talquetamab treatment.
- Results showed that while normal IL-6 levels had no significant impact on drug interactions, elevated IL-6 could moderately affect specific liver enzymes, with potential effects peaking 7 to 9 days after the start of treatment.
Article Synopsis
- Talquetamab is a newly approved bispecific antibody that targets T cells and is specifically effective against multiple myeloma (MM), but it can cause unique side effects related to skin, nails, and oral health that need careful management.
- The review discusses findings from the MonumenTAL-1 clinical trial, which reported over 71% effectiveness in patients with relapsed/refractory MM, highlighting that most adverse events were low-grade and manageable.
- It emphasizes the crucial role of oncology nurses in monitoring and supporting patient care related to talquetamab treatment, aiming to enhance the quality of life and survival rates for patients undergoing this therapy.
Article Synopsis
- Talquetamab is a bispecific antibody that targets the GPRC5D antigen in patients with relapsed/refractory multiple myeloma, showing over 71% overall response rates in clinical trials.
- Adverse events (AEs) associated with talquetamab mainly included dermatologic and oral issues, although the majority were low grade and manageable through various treatment strategies.
- Effective management of more serious AEs, like cytokine release syndrome and neurotoxicity, along with proper education for healthcare providers, can help maintain the quality of life for patients undergoing treatment.
Article Synopsis
- Multiple myeloma is a type of cancer that affects the bone marrow and has a 5-year survival rate of about 60%, but there are challenges with treatment.
- Researchers are focusing on a new target in the fight against this cancer called GPRC5D, which could help make therapies more effective.
- Early trials with GPRC5D-targeting treatments show promising results, with many patients responding well and experiencing fewer infections compared to other treatments, but some side effects related to skin and mouth have been observed.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Lancet Haematol
November 2023
Article Synopsis
- The study investigated the effectiveness and optimal dosage of cusatuzumab, an anti-CD70 antibody, combined with azacitidine for treating acute myeloid leukaemia in patients not eligible for intensive chemotherapy.
- Conducted across 40 hospitals in seven countries, the randomized trial assigned 103 adult patients to receive either 10 mg/kg or 20 mg/kg doses of cusatuzumab alongside azacitidine in 28-day cycles, aiming to evaluate complete remission rates.
- Although 55% of patients experienced significant treatment results, the study was halted after part one due to changes in the treatment landscape that made continuing with further phases impractical.
Background: A liquid formulation of 6-mercaptopurine (6-MP) was recently approved by the Food and Drug Administration (Purixan®) based on bioavailability (BA) data from healthy adults. We examined the pharmacokinetics (PK) and BA of 6-MP in children with acute lymphoblastic leukemia (ALL) comparing a marketed tablet, two extemporaneously prepared liquid formulations, and data from the approved liquid formulation.
Methods: Twenty-two children (6-17 years) participated in a randomized two-way, crossover study of two cohorts.
In the last two decades, tremendous advances have been made in the treatment of acute lymphocytic leukaemia (ALL) in children with 5 year 'cure' rates in excess of 90%. The maintenance of remission is due, in part, to individualisation of therapy which must consider age, body size, genetic constitution and the impact of disease on drug disposition and action. This review, focused on treatment of ALL and one of the therapeutic mainstays, 6-mercaptopurine, illustrates the importance of obesity as a modulating factor in dose individualisation.
View Article and Find Full Text PDFCommon acquired causes of thrombosis in children.
Curr Probl Pediatr Adolesc Health Care
August 2013
Compared to adults, venous thromboembolism in the pediatric population is a rare event. Cancer, cardiac disease, antiphospholipid antibodies, and indwelling catheters are established risk factors for thromboembolism in children. We examined the literature related to thrombophilia in children, childhood cancer and thrombosis, cardiac disease and thrombosis, and antiphospholipid antibody syndrome in children.
View Article and Find Full Text PDF